Biologics and Biosimilars: FDA Initiatives and Guidance, Approvals and Exclusivity, Patent Prosecution, Litigation
February 15, 2024
Webinar
Strafford Publications
As part of Strafford Publications’ virtual programming, Finnegan partners Mark Feldstein and David Weingarten will discuss updates on FDA practice and patent law relating to biologics and biosimilars. For more information, or to register, please see Strafford’s website.
Tags
IPR estoppel, Federal Circuit History, Patent Trial and Appeal Board (PTAB), Food and Drug Administration (FDA)
